4.077

1.09% -0.043

Precigen Inc (PGEN)

Overview News Price History Option Chain Financials Discussions Forecast

Precigen Inc stock is traded at $4.077, with a volume of 829.77K. It is down -1.09% in the last 24 hours and up +22.74% over the past month. Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.

Previous Close:

$4.12

Open:

$4.28

24h Volume:

829.77K

Relative Volume:

0.18

Market Cap:

$1.44B

Revenue:

$9.68M

Net Income/Loss:

$-250.64M

P/E Ratio:

-2.9126

EPS:

-1.3998

Net Cash Flow:

$-89.83M

1W Performance:

+3.69%

1M Performance:

+22.74%

6M Performance:

+26.55%

1Y Performance:

+248.29%

1-Day Range:

$4.015

$4.34

1-Week Range:

$3.75

$4.34

52-Week Range:

$1.12

$5.465

Precigen Inc Stock (PGEN) Company Profile

Name

Precigen Inc

Sector

Healthcare (1110)

Industry

Biotechnology (624)

Phone

301-556-9900

Address

20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD

Employee

Twitter

@precigen

Next Earnings Date

2026-03-25

Latest SEC Filings

PGEN's Discussions on Twitter

Compare PGEN vs VRTX, REGN, ARGX, ALNY, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PGEN Precigen Inc	4.08	1.46B	9.68M	-250.64M	-89.83M	-1.3998
VRTX Vertex Pharmaceuticals Inc	439.31	109.85B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	768.95	80.38B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	783.00	47.60B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	327.14	42.63B	3.71B	313.75M	465.38M	2.2571
INSM Insmed Inc	162.41	35.19B	606.42M	-1.28B	-997.58M	-6.403

Precigen Inc Stock (PGEN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-15-25	Upgrade	JP Morgan	Underweight → Neutral
Mar-22-24	Downgrade	JP Morgan	Neutral → Underweight
May-23-23	Initiated	JP Morgan	Neutral
Nov-18-22	Initiated	Cantor Fitzgerald	Overweight
Feb-25-21	Initiated	Stifel	Buy
Feb-22-21	Initiated	Wells Fargo	Overweight
Feb-18-21	Initiated	B. Riley Securities	Buy
May-08-20	Initiated	H.C. Wainwright	Buy

View All

Precigen Inc Stock (PGEN) Latest News

08:02 AM

Precigen sees Q1 revenue exceeding $18M, consensus $20.8M - Yahoo Finance

08:02 AM

Apr 07, 2026

Precigen Reports 'Robust Uptake' of New Drug for Rare Respiratory Disease; First Quarter Revenue Expected to Top $18 Million - marketscreener.com

Apr 07, 2026

Precigen Reports Strong Demand for New Rare Disease Drug - National Today

Apr 07, 2026

Precigen reports $3.4M in PAPZIMEOS sales for Q4 2025 By Investing.com - Investing.com South Africa

Apr 07, 2026

Precigen (PGEN) Eyes Revenue Growth with PAPZIMEOS Success - GuruFocus

Apr 07, 2026

Precigen (PGEN) Sees Strong Demand for Papzimeos Immunotherapy - GuruFocus

Apr 07, 2026

(PGEN) Precigen Expects Q1 Revenue to Exceed $18M, vs. FactSet Est of $20.8M - marketscreener.com

Apr 07, 2026

Rare disease drug aimed at reducing surgeries lifts Precigen Q1 view above $18M - Stock Titan

Apr 07, 2026

Apr 06, 2026